This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Omeros (OMER) Ahead of Earnings?
by Zacks Equity Research
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
Company News for Mar 4, 2020
by Zacks Equity Research
Companies in the news are: SCON, OMER, QGEN, TLRY
Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 47.37% and 3.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 64.44% and 8.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Omeros (OMER) Q3 Earnings Expected to Decline
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Surges: Stock Moves 10.2% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 9.09% and -5.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.
These 3 Stocks Surged During Thursday's Sell-Off
by Benjamin Rains
Stocks saw rather large declines on Thursday, driven by concerns surrounding possible tariff-related retaliation from China against U.S. giants such as Boeing (BA), while Facebook's (FB) data breach woes escalated. These bellwethers helped contribute to a nearly 2.5% decline in the S&P 500 index as investors continue to assess the cost of rising interest rates and possible trade wars.
Omeros Inks Agreement With FDA for OMS721 Phase III Trial
by Zacks Equity Research
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
by Zacks Equity Research
Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.